[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"immune-deficiency\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:immune-deficiency":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,51,91,118,177,206,236],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100569096","lets-get-real-family-health-communication-tool-in-pediatric-stem-cell-transplant-and-cellular-therapy-100569096",false,"NCT06689800","Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy","Let's Get REAL: A Pilot Trial of a Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy","Inclusion Criteria Youth:\n\n* Children or adolescents 8-17 years of age referred for SCTCT.\n* Diagnosis of malignant or nonmalignant disorder.\n* Referred for any type of SCTCT. Autologous and allogeneic stem cell and cellular therapies are eligible.\n* Planning to meet with a provider to discuss SCTCT.\n* Must have the ability to understand and willingness to consent to participate after reviewing an IRB approved informed assent document.\n* Must speak English and be cognitively able to participate.\n\nInclusion Criteria Parents:\n\n* Parent or guardian of a child 8-17 years of age with any diagnosis referred for any type of SCTCT. Diagnoses may include malignant and nonmalignant disorders. Autologous and allogeneic stem cell and cellular therapies are eligible. Parent or guardian is defined as an adult who usually cares for the youth and has authority to make medical decisions for them.\n* Must have the ability to understand and willingness to consent to participate after reviewing an IRB approved informed consent document.\n* Must speak English and be cognitively able to participate.\n\nExclusion Criteria Youth:\n\n* Active medical problems severe enough to preclude study participation at the time of recruitment.\n\n  * Patients who are otherwise eligible, but whose primary transplant physician does not want them to participate in the study.\n* Lacks cognitive capacity to complete study activities, as determined by consenting professional.\n\nExclusion Criteria Parents:\n\n* Their youth referred for SCTCT does not assent to participate.","ALL","8 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"NA","The investigators will conduct a pilot feasibility and efficacy trial of a newly developed family health communication tool (called Let's Get REAL) in increasing youth involvement in real-time stem cell transplant and cellular therapy decisions (SCTCT). The investigators will pilot the intervention among 24 youth and their parents, stratified by youth age (stratum 1, 8-12 years of age and stratum 2, 13-17 years of age).",[26,27,28,29,30,31],"Hematologic Malignancy","Solid Tumor","Sickle Cell Disease","Aplastic Anemia","Immune Deficiency","Metabolic Disorder",[33,34,35,36,37],"Pediatric","Family","Decision making","Health Communication","Intervention","RECRUITING","2026-06-01",{"date":41,"type":42},"2026-06-04","ACTUAL",{"date":44,"type":42},"2024-11-26",{"date":46,"type":20},"2026-11-30",{"name":48,"class":49},"Washington University School of Medicine","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":16,"minAge":4,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":50},"100484165","allergy-and-immunology-natural-history-study-100484165","NCT05584488","Allergy and Immunology Natural History Study","Natural History Study for Genetic Diseases of Allergic Inflammation and Immune Dysregulation","Inclusion Criteria:\n\n* Subjects, ages birth to 99 years old, known to have or suspected of having an inherited disorder of allergic inflammation, or mast cell homeostasis, or activation or immune dysregulation.\n* Blood relatives of enrolled subjects will be eligible for enrollment.\n* There will be no discrimination as to age, gender, race, or disability.\n* Subjects\u002Fguardians must be willing and able to give informed consent.\n* Subjects must agree to have their blood stored for future studies of the immune system and\u002For other medical conditions.\n\nExclusion Criteria:\n\n• The presence of an acquired abnormality of the immune system, such as cytotoxic chemotherapy or malignancy may be grounds for possible exclusion if, in the opinion of the investigator, the presence of such a disease process would interfere with evaluation.",true,"99 Years",{"count":61,"type":20},10000,"OBSERVATIONAL","This protocol is a natural history study designed to evaluate subjects (and some family members) with suspected or identified genetic diseases of allergic inflammation or Immune Dysregulation. Patients determined by clinical history and outside evaluations to be of interest will be consented and enrolled into this study. Blood specimens, stored blood products and derivatives, saliva, hair, fingernail clippings, cord blood, umbilical cord, bone marrow, tissue biopsies and\u002For buccal swabs from such patients and\u002For their family members will be obtained for research studies related to understanding genetic and immunopathogenic bases of these diseases. Outside medical records may be obtained, and patient evaluations may be performed to correlate to research laboratory testing results.",[30,65,66],"Immune Dysregulation Disorder","Allergic Inflammation",[68,69,70,71,72,73,74,75,76,77,78,79,80,81],"Eosinophilic Disease","Anaphylaxis","Elevated IgE levels","Autoimmune diseases","Allergy","Asthma","Atopic Dermatitis","Allergic Fhinitis","Food Allergy","Immunodeficiency Diseases","Immunodysregulatory Diseases","Piebaldism","Urticaria","Angioedema","2026-02-02",{"date":84,"type":42},"2026-02-04",{"date":86,"type":42},"2010-07-16",{"date":88,"type":20},"2027-01",{"name":90,"class":49},"Columbia University",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":16,"minAge":98,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":21,"phases":102,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":50},"100587323","phase-1-r-mvst-cells-for-treatment-of-viral-infections-in-children-and-young-adults-100587323","NCT06926894","R-MVST Cells for Treatment of Viral Infections in Children and Young Adults","Single Center Phase I Study of Adoptive Immunotherapy of Refractory Viral Infection With ex Vivo Expanded Rapidly Generated Virus Specific T (R-MVST) Cells for Immunodeficient Children and Young Adults","Inclusion Criteria:\n\n* Children and young adults (3 months to \\\u003C26 years) of all ethnic groups will be eligible for the treatment\n* Patients with history of HCT or SOT who demonstrate evidence of viral reactivation and\u002For infection manifesting as end-organ or systemic disease due to one or more of the following viruses: EBV, CMV, ADV or BK virus and suboptimal response to the standard of care therapy.\n* Recurrent or Multiple Viral Infection. RVI defined as occurrence of more than one episode of reactivation that required intervention or symptomatic disease in recipient of allogeneic HCT that required standard of care treatment. MVI defined as more than one virus reactivating (defined by PCR positivity) or causing symptomatic systemic or end-organ disease. At least one of those viral reactivations required standard of care intervention. No standard of care therapy is defined for ADV and BK. Patients with multiple infections\u002Freactivations will be eligible as long as at least one of those viral infections meet the criterium of \"refractory\".\n\nExclusion Criteria:\n\n* Patients with other uncontrolled infections, except for CMV, EBV, ADV or BK. For bacterial infections, patients must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to the day of infusion. For fungal infections, patients must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to R-MVST infusion. Progressing infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.\n* Patients who receive corticosteroids at ≥ 0.5mg\u002Fkg prednisone or equivalent.\n* Patients who received anti-thymocyte globulin (ATG, Alemtuzumab (Campath), or other T-Cell immunosuppressive monoclonal antibodies in the last 28 days.\n* Patients who received methotrexate, or other antimetabolite-type immunosuppressants that are toxic to proliferating T cells in the last 7 days.\n* Patients who received extracorporeal photopheresis within the last 28 days.\n* Patients who received checkpoint inhibitor agents (e.g., nivolumab, pembrolizumab, ipilimumab) within 3 drug half-lives of the most recent dose to the infusion of R-MVST.\n* Received donor lymphocyte infusion in last 28 days.\n* Evidence of GVHD ≥ grade 2\n* Evidence of biopsy-proven acute rejection in SOT recipients\n* Active and uncontrolled relapse of malignancy\n* Patients who are pregnant, or breastfeeding.\n* Female of childbearing potential, or male with a female partner of childbearing potential, unwilling to use a highly effective method of contraception.\n* Uncontrolled intercurrent illness including, but not limited to symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Patients who have received investigational (IND) product within 14 days of infusion of the the R-MVST cells.\n* Unable or unwilling to receive infusions at Morgan Stanley Children's Hospital.","3 Months","26 Years",{"count":101,"type":20},18,[103],"PHASE1","The primary objective is to determine the safety and feasibility of administering R-MVST cells to patients with refractory viral reactivation and\u002For symptomatic disease caused by Epstein Barr Virus (EBV), cytomegalovirus (CMV), adenovirus (ADV) or BK virus. R-MVST cells will be generated on-demand from the closest partially human leukocyte antigen (HLA)-matched (minimum haploidentical) healthy donors or from the original allo-transplant donor if available. The investigator will closely monitor the recipients for potential toxicities including graft-versus-host disease (GVHD) post-infusion.\n\nSecondary objectives are to determine the effect of R-MVST infusion on viral load, possible recovery of antiviral immunity post-infusion and for evidence of clinical responses and overall survival. Recipients will be monitored for secondary graft failure at day 28 post R-MVST infusion.",[106,107,108,109,30],"Epstein-Barr Virus","Cytomegalovirus Infections","Adenovirus","BK Virus Infection","2025-07-29",{"date":112,"type":42},"2025-07-31",{"date":114,"type":42},"2025-04-20",{"date":116,"type":20},"2030-12",{"name":90,"class":49},{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":126,"targetDuration":128,"studyType":62,"phases":4,"briefSummary":129,"conditions":130,"keywords":157,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":50},"100592939","shwachman-diamond-syndrome-global-patient-survey-and-partnering-platform-100592939","NCT06999954","Shwachman-Diamond Syndrome Global Patient Survey and Partnering Platform","The Shwachman-Diamond Syndrome Global Patient Survey and Partnering Platform Program (SDS-GPS Program)","SDS-GPS","Inclusion Criteria:\n\nThe Program invites patients of all ages who have a confirmed diagnosis of the below, using established diagnostic guidelines, plus their parents\u002Fcaregivers.\n\n* Patients with a confirmed Shwachman-Diamond Syndrome (SDS) diagnosis, including a genetic or clinical diagnosis. The initial focus will be on patients with a genetic diagnosis of SDS based on biallelic mutations in SBDS or EFL1.\n* Patients with a confirmed diagnosis of an SDS-like syndrome (e.g. due to mutations in DNAJC21, SRP54, or other genes that may be associated with an SDS-like syndrome in the future).\n* Patients with other heritable hematological malignancy disorders (such as RUNX1-FPD, Fanconi Anemia) and\u002For congenital neutropenias (such as ELANE neutropenia) are also eligible for inclusion.\n* Caregivers, parents, and close relatives of all patients above, including of patients alive or deceased.\n\nExclusion Criteria:\n\n● People who do not meet the above criteria.",{"count":127,"type":20},8000,"120 Years","The Shwachman-Diamond Syndrome Global Patient Survey and Collaboration Program (SDS-GPS) is an opportunity for patients and their families - from anywhere in the world - to share their experience living with SDS via a safe, secure, and convenient online platform, to\n\n* expand the understanding of SDS\n* improve the lives of people with SDS, and\n* accelerate the development of new therapies and cures for SDS.\n\nBy joining, participants will receive early access to relevant information about new clinical trials and other research opportunities (such as clinical registries) based on their profile, accelerating research and increasing clinical trial impact and recruitment success.\n\nThe platform, consent forms, and surveys are available in five languages: English, Spanish, French, German, and Italian. More languages to come.",[131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,30,152,153,154,155,156],"Shwachman-Diamond Syndrome","SDS","IBMF","Congenital Neutropenia","Heme Malignancy","Shwachman Syndrome","Inherited Bone Marrow Failure","Exocrine Pancreatic Insufficiency","WHIM","ELANE","SBDS Gene Mutation","EFL1 Gene Mutation","DNAJC21 Gene Mutation","SRP54 Gene Mutation","Inherited Cancer Syndrome","Inherited Cancer-Predisposing Syndrome","Neutropenia, Severe Chronic","Neutropenia Other","Neutropenia Chronic Benign","Ribosome Alteration","Ribosomopathy","Inherited BMF Syndrome","Inherited Immunodeficiency Diseases","Cognitive Delay, Mild","Myelodysplastic Syndromes","Pancytopenia",[131,158,136,132,133,137,134,30,159,160,139,140,161,162,163,164,165,166,167],"Shwachman Diamond Syndrome","SDS-like syndrome","genetic cancer predisposition","SBDS","EFL1","SRP54","DNAJC21","severe chronic neutropenia","exocrine pancreatic insufficiency","ribosomopathy","2025-05-23",{"date":170,"type":42},"2025-05-31",{"date":172,"type":42},"2024-02-07",{"date":174,"type":20},"2088-12",{"name":176,"class":49},"Shwachman-Diamond Syndrome Alliance Inc",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":185,"minAge":186,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":205},"100537477","x-linked-moesin-associated-immunodeficiency-100537477","NCT06278337","X-linked Moesin Associated Immunodeficiency","Etude Multicentrique Internationale rétrospective Des Patients Atteints de déficit Immunitaire associé à la moésine lié au Chromosome X (X Maid Pour X-linked Moesin Associated Immunodeficiency)","X-MAIDReg","Inclusion Criteria:\n\n* Male patient with a mutation in the MOESIN gene (MSN)\n* No objection to the collection of personal health data\n\nExclusion Criteria:\n\n\\-","MALE","4 Years","80 Years",{"count":189,"type":20},16,"Moesin deficiency was initially described in 7 male participants aged 4 to 69 years and is characterized by lymphopenia of the 3 lineages and moderate neutropenia. Genetically, 6 out of 7 participants had the same missense mutation in the moesin gene located on the X chromosome. The 7th patient has a mutation leading to the premature introduction of a STOP codon into the protein.Clinically the 7 participants with X-linked moesin-associated immunodeficiency all presented with recurrent bacterial infections of the respiratory, gastrointestinal or urinary tracts, and some had severe varicella.Therapeutically, in the absence of a molecular diagnosis and due to his SCID-like phenotype, one patient was treated with geno-identical hematopoietic stem cell transplantation . The remaining are untreated or treated with immunoglobulin substitution and\u002For prophylactic antibiotics.\n\nSince this study, the moesin gene has been integrated into DNA chips used for the molecular diagnosis of immune deficiencies in several countries. Physicians in Canada, the United States, Japan, South Africa and Europe have contacted us with a total of 16 known participants to date. Because of their very low severe, uncontrolled CMV infection and the absence of treatment recommendations, two 2 American participants were treated with allogeneic transplantation with severe post-transplant complications (1), and one of the participants died as a result of the transplant. Management of XMAID participants therefore varies widely from country to country, depending on age at diagnosis and clinical picture. It ranges from no treatment treatment (associated with recurrent infections and skin manifestations), IgIv substitution and\u002For antibiotic prophylaxis antibiotic prophylaxis, with low toxicity and apparent efficacy, and allogeneic transplantation, with all the risks risks involved (graft-related toxicity, graft versus host, disease, rejection, risk of infection). The Investigators therefore feel it is important to review the diagnosis, clinical presentation and management of X-MAID participants. The study the investigator propose will enable to understand the presentation of X-MAID participants, establish guidelines and provide the best treatment for each patient according to his or her clinical picture",[30,192,193,194],"Autoimmune Diseases","Infections","Diagnosis","2025-04-23",{"date":197,"type":42},"2025-04-25",{"date":199,"type":42},"2021-08-12",{"date":201,"type":20},"2027-01-12",{"name":203,"class":204},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV",10,{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":16,"minAge":214,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":21,"phases":217,"briefSummary":219,"conditions":220,"keywords":221,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":50},"100471626","phase-2-efficacy-of-qbkpn-site-specific-immunomodulator-in-improving-innate-immune-function--reducing-respiratory-tract-infection-in-older-adults-100471626","NCT05421325","Efficacy of QBKPN Site-Specific Immunomodulator in Improving Innate Immune Function & Reducing Respiratory Tract Infection in Older Adults","Assessment of QBKPN Site-Specific Immunomodulator (SSI) Efficacy in Improving Innate Immune Function and Reducing All-Cause Respiratory Tract Infection Morbidity in Adults 65 Years of Age or Older Residing in the Community, in Independent-Living, Assisted-Living and Long-term Care Facilities","RESILIENCE","Inclusion Criteria:\n\n1. Be a resident of the community or a long-term care, independent-living or assisted living facility participating in the study\n2. Be aged 65 years or older\n3. Be able to provide written, informed consent themselves\n4. Male subjects engaged in vaginal intercourse with women of childbearing potential must be surgically sterile or agree to practice effective barrier contraception during the entire study treatment period (4 weeks) and one month after the last dose of study drug or agree to completely abstain from vaginal intercourse with women of childbearing potential during this period.\n\nExclusion Criteria:\n\n1. Life expectancy of less than 3 months due to terminal illness as determined by the Study Investigator\n2. Taking biologic immunosuppressive agents (e.g., Anti-Tumour Necrosis Factor Alpha (anti-TNFa) antibodies, rituximab, ibrutinib, imatinib) calcineurin inhibitors, myelosuppressants (e.g., methotrexate, mycophenolate), or other systemic immunosuppressants. Note: NSAIDs, colchicine, aspirin and oral glucocorticoids at a dose equivalent to less than or equal to 5mg prednisone per day are allowed\n3. Currently being treated or less than 30 days from being treated for confirmed or probable infection with systemic (i.e., not topical) antibiotics or antivirals\n4. Have a known allergy or hypersensitivity to killed whole-cell bacterial vaccines\n5. Any condition that, in the opinion of the Investigator, would preclude the person from participation in the study due to safety or monitoring concerns\n6. Any treatment with experimental or investigational therapies within 3 months prior to Screening and\u002For any planned treatment with experimental or investigational therapies during the entire course of study participation\n7. On current treatment for active malignancies (e.g., chemotherapy, radiation) or planned cancer surgery during the study period. Note: People on exclusively hormonal therapy for breast or prostate cancer are allowed. People with prior or planned surgery for localized squamous cell or basal cell carcinoma of the skin are allowed","65 Years",{"count":216,"type":20},72,[218],"PHASE2","This study is designed to test whether QBKPN SSI can improve immune function in older adults, including how well it can protect against respiratory and other infections, whether it improves the body's response to COVID-19 vaccines, what effect it has on maintaining or improving quality of life, activity level and health status and whether it has an effect on glycemic control.\n\nQBKPN is a new medication in a class known as Site-Specific Immunomodulators (SSI). SSIs are designed to train and\u002For improve innate immune function to reduce the risk of infections, improve immune response to cancer, and slow the progression of chronic inflammatory diseases.\n\nIt is believed that QBKPN SSI can work with the immune system to help protect against respiratory and other infections.",[30],[222,223,224,225],"Immunosenescence","immunodegeneration","immune dysfunction","older adult","2025-01-21",{"date":228,"type":42},"2025-01-22",{"date":230,"type":42},"2023-04-11",{"date":232,"type":20},"2026-02",{"name":234,"class":235},"Qu Biologics Inc.","INDUSTRY",{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":242,"eligibilityCriteria":243,"healthyVolunteers":58,"sex":16,"minAge":244,"maxAge":4,"enrollmentInfo":245,"targetDuration":247,"studyType":62,"phases":4,"briefSummary":248,"conditions":249,"keywords":253,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":50},"100396964","immune-homeostasis-in-sepsis-and-septic-shock-100396964","NCT04448951","Immune Homeostasis in Sepsis and Septic Shock","Immune Homeostasis in Patients With Sepsis and Septic Shock: a Single Center Observational Study","IMHOTEP","Inclusion Criteria:\n\n* sepsis\u002Fseptic shock (SEPSIS-3)\n* age ≥18\n* informed consent\n* inclusion within first 24hrs after development\u002Fdiagnosis of septic shock\n\nExclusion Criteria:\n\n* disagreement of the patient or legal representative with the entry into the study\n* patients with primary or secondary immunodeficiency\n* presence of active haematological malignancy or an active non-haematological malignancy","18 Years",{"count":246,"type":20},200,"90 Days","Detailed description of immune response and its dynamics in sepsis and septic shock patiens by means of transcriptomics, flow-cytometry and cytokine analysis.",[250,251,252,30],"Sepsis","Immunologic Paralysis","Immunologic Suppression",[254,255,256,257,258,259,260],"sepsis","septic shock","immune response","immunoparalysis","transcriptomics","flow-cytometry","immunomodulation","2024-08-20",{"date":263,"type":42},"2024-08-21",{"date":265,"type":42},"2020-09-01",{"date":267,"type":20},"2027-12-31",{"name":269,"class":49},"Charles University, Czech Republic"]